Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 3/2005

01.03.2005 | Original Article

Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines

verfasst von: Zhenfeng Duan, Diana E. Lamendola, Yifei Duan, Rushdia Z. Yusuf, Michael V. Seiden

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 3/2005

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To identify genes involved in the paclitaxel resistance phenotype.

Methods

High-density Affymetrix HG-U95Av2 microarrays were used to quantify gene expression in the resulting cell lines, SKOV-3TR, OVCAR8TR and MCF-7TR, and their drug-sensitive parental lines, SKOV-3, OVCAR8 and MCF-7.

Results

Three paclitaxel-resistant human ovarian and breast cancer cell lines were established. We identified 790 (SKOV-3TR), 689 (OVCAR8TR) and 964 (MCF-7TR) transcripts that were more than twofold overexpressed relative to their expression in the corresponding parental cell line. A comparison of these transcripts identified eight genes that were significantly overexpressed in all three drug-resistant daughter cell lines. These genes included MDR1, a gene often implicated in both in vitro and in vivo resistance to multiple chemotherapeutics, including paclitaxel. The remaining seven genes have not been previously associated with resistance to paclitaxel in human cancer. Furthermore, we identified 815 (SKOV-3TR), 430 (OVCAR8TR) and 332 (MCF-7TR) transcripts that were more than twofold decreased relative to their expression in the corresponding parental cell line. Comparison of these transcripts identified three genes that were significantly underexpressed in all three drug-resistant cell lines, none of which have been previously associated with paclitaxel resistance.

Conclusions

Our results confirm that the paclitaxel resistance phenotype is associated with a large number of transcriptional changes. In addition, acquired paclitaxel resistance was associated with distinct transcriptional changes in each of the cell lines studied, suggesting that paclitaxel resistance is a complex phenotype that can arise through multiple mechanisms.
Literatur
1.
Zurück zum Zitat McGuire WP, Blessing JA, Moore D, Lentz SS, Photopulos G (1996) Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol 14:792PubMed McGuire WP, Blessing JA, Moore D, Lentz SS, Photopulos G (1996) Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol 14:792PubMed
2.
Zurück zum Zitat Loe DW, Deeley RG, Cole SP (1996) Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer 32A:945CrossRefPubMed Loe DW, Deeley RG, Cole SP (1996) Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer 32A:945CrossRefPubMed
3.
Zurück zum Zitat Volm M (1998) Multidrug resistance and its reversal. Anticancer Res 18:2905PubMed Volm M (1998) Multidrug resistance and its reversal. Anticancer Res 18:2905PubMed
5.
Zurück zum Zitat Lamendola DE, Duan Z, Yusuf RZ, Seiden MV (2003) Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. Cancer Res 63:2200PubMed Lamendola DE, Duan Z, Yusuf RZ, Seiden MV (2003) Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. Cancer Res 63:2200PubMed
6.
Zurück zum Zitat Watts GS, Futscher BW, Isett R, Gleason-Guzman M, Kunkel MW, Salmon SE (2001) cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis signaling pathways. J Pharmacol Exp Ther 299:434PubMed Watts GS, Futscher BW, Isett R, Gleason-Guzman M, Kunkel MW, Salmon SE (2001) cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis signaling pathways. J Pharmacol Exp Ther 299:434PubMed
7.
Zurück zum Zitat McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1CrossRefPubMed McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1CrossRefPubMed
8.
Zurück zum Zitat Brockstein B, Haraf DJ, Stenson K, Fasanmade A, Stupp R, Glisson B, Lippman SM, Ratain MJ, Sulzen L, Klepsch A, Weichselbaum RR, Vokes EE (1998) Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol 16:735PubMed Brockstein B, Haraf DJ, Stenson K, Fasanmade A, Stupp R, Glisson B, Lippman SM, Ratain MJ, Sulzen L, Klepsch A, Weichselbaum RR, Vokes EE (1998) Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol 16:735PubMed
9.
Zurück zum Zitat Dumontet C, Duran GE, Steger KA, Beketic-Oreskovic L, Sikic BI (1996) Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res 56:1091PubMed Dumontet C, Duran GE, Steger KA, Beketic-Oreskovic L, Sikic BI (1996) Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res 56:1091PubMed
10.
Zurück zum Zitat Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, Poruchynsky MS (1997) Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272:17118CrossRefPubMed Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, Poruchynsky MS (1997) Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272:17118CrossRefPubMed
11.
Zurück zum Zitat Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV (2003) Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 3:1PubMed Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV (2003) Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 3:1PubMed
12.
Zurück zum Zitat Duan Z, Feller AJ, Penson RT, Chabner BA, Seiden MV (1999) Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res 5:3445PubMed Duan Z, Feller AJ, Penson RT, Chabner BA, Seiden MV (1999) Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res 5:3445PubMed
13.
Zurück zum Zitat Duan Z, Feller AJ, Toh HC, Makastorsis T, Seiden MV (1999) TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line. Gene 229:75CrossRefPubMed Duan Z, Feller AJ, Toh HC, Makastorsis T, Seiden MV (1999) TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line. Gene 229:75CrossRefPubMed
14.
Zurück zum Zitat Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res 47:943PubMed Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res 47:943PubMed
15.
Zurück zum Zitat Duan Z, Lamendola DE, Penson RT, Kronish KM, Seiden MV (2002) Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells. Cytokine 17:234CrossRefPubMed Duan Z, Lamendola DE, Penson RT, Kronish KM, Seiden MV (2002) Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells. Cytokine 17:234CrossRefPubMed
16.
Zurück zum Zitat Duan Z, Lamendola DE, Yusuf RZ, Penson RT, Preffer FI, Seiden MV (2002) Overexpression of human phosphoglycerate kinase 1 (PGK1) induces a multidrug resistance phenotype. Anticancer Res 22:1933PubMed Duan Z, Lamendola DE, Yusuf RZ, Penson RT, Preffer FI, Seiden MV (2002) Overexpression of human phosphoglycerate kinase 1 (PGK1) induces a multidrug resistance phenotype. Anticancer Res 22:1933PubMed
17.
Zurück zum Zitat Duan Z, Duan Y, Lamendola DE, Yusuf RZ, Naeem R, Penson RT, Seiden MV (2003) Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res 9:2778PubMed Duan Z, Duan Y, Lamendola DE, Yusuf RZ, Naeem R, Penson RT, Seiden MV (2003) Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res 9:2778PubMed
18.
Zurück zum Zitat Dolci ED, Abramson R, Xuan Y, Siegfried J, Yuenger KA, Yassa DS, Tritton TR (1993) Anomalous expression of P-glycoprotein in highly drug-resistant human KB cells. Int J Cancer 54:302PubMed Dolci ED, Abramson R, Xuan Y, Siegfried J, Yuenger KA, Yassa DS, Tritton TR (1993) Anomalous expression of P-glycoprotein in highly drug-resistant human KB cells. Int J Cancer 54:302PubMed
19.
Zurück zum Zitat Baird RD, Kaye SB (2003) Drug resistance reversal—are we getting closer? Eur J Cancer 39:2450CrossRefPubMed Baird RD, Kaye SB (2003) Drug resistance reversal—are we getting closer? Eur J Cancer 39:2450CrossRefPubMed
20.
Zurück zum Zitat Penson R, Skates SJ, Glyptis T, Fuller AF, Goodman A, Seiden MV (2004) Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol 93:98CrossRefPubMed Penson R, Skates SJ, Glyptis T, Fuller AF, Goodman A, Seiden MV (2004) Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol 93:98CrossRefPubMed
21.
Zurück zum Zitat Seiden MV, Swenerton KD, Matulonis U, Campos S, Rose P, Batist G, Ette E, Garg V, Fuller A, Harding MW, Charpentier D (2002) A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol 86:302CrossRefPubMed Seiden MV, Swenerton KD, Matulonis U, Campos S, Rose P, Batist G, Ette E, Garg V, Fuller A, Harding MW, Charpentier D (2002) A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol 86:302CrossRefPubMed
22.
Zurück zum Zitat Smith AJ, van Helvoort A, van Meer G, Szabo K, Welker E, Szakacs G, Varadi A, Sarkadi B, Borst P (2000) MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem 275:23530CrossRefPubMed Smith AJ, van Helvoort A, van Meer G, Szabo K, Welker E, Szakacs G, Varadi A, Sarkadi B, Borst P (2000) MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem 275:23530CrossRefPubMed
23.
Zurück zum Zitat Arai Y, Masuda M, Sugawara I, Arai T, Motoji T, Tsuruo T, Oshimi K, Mizoguchi H (1997) Expression of the MDR1 and MDR3 gene products in acute and chronic leukemias. Leuk Res 21:313CrossRefPubMed Arai Y, Masuda M, Sugawara I, Arai T, Motoji T, Tsuruo T, Oshimi K, Mizoguchi H (1997) Expression of the MDR1 and MDR3 gene products in acute and chronic leukemias. Leuk Res 21:313CrossRefPubMed
24.
Zurück zum Zitat Shibata K, Kikkawa F, Nawa A, Suganuma N, Hamaguchi M (1997) Fibronectin secretion from human peritoneal tissue induces Mr 92,000 type IV collagenase expression and invasion in ovarian cancer cell lines. Cancer Res 57:5416PubMed Shibata K, Kikkawa F, Nawa A, Suganuma N, Hamaguchi M (1997) Fibronectin secretion from human peritoneal tissue induces Mr 92,000 type IV collagenase expression and invasion in ovarian cancer cell lines. Cancer Res 57:5416PubMed
25.
Zurück zum Zitat Vargas-Roig LM, Fanelli MA, Lopez LA, Gago FE, Tello O, Aznar JC, Ciocca DR (1997) Heat shock proteins and cell proliferation in human breast cancer biopsy samples. Cancer Detect Prev 21:441PubMed Vargas-Roig LM, Fanelli MA, Lopez LA, Gago FE, Tello O, Aznar JC, Ciocca DR (1997) Heat shock proteins and cell proliferation in human breast cancer biopsy samples. Cancer Detect Prev 21:441PubMed
26.
Zurück zum Zitat Nylandsted J, Rohde M, Brand K, Bastholm L, Elling F, Jaattela M (2000) Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2. Proc Natl Acad Sci U S A 97:7871CrossRefPubMed Nylandsted J, Rohde M, Brand K, Bastholm L, Elling F, Jaattela M (2000) Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2. Proc Natl Acad Sci U S A 97:7871CrossRefPubMed
Metadaten
Titel
Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines
verfasst von
Zhenfeng Duan
Diana E. Lamendola
Yifei Duan
Rushdia Z. Yusuf
Michael V. Seiden
Publikationsdatum
01.03.2005
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 3/2005
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-004-0878-y

Weitere Artikel der Ausgabe 3/2005

Cancer Chemotherapy and Pharmacology 3/2005 Zur Ausgabe

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Brustkrebs-Prävention wird neu gedacht

04.06.2024 ASCO 2024 Kongressbericht

Zurzeit untersuchen Forschende verschiedene neue Ansätze zur Prävention von Brustkrebs bei Personen mit hohem Risiko. Darunter Denosumab, die prophylaktische Bestrahlung der Brust – und Impfungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.